Valuation: Adaptive Biotechnologies Corporation

Market Cap 4.53B 4.06B 3.71B 3.39B 6.39B 426B 6.59B 44.75B 17.84B 227B 17B 16.64B 717B P/E 2026 *
-51.9x
P/E 2027 * -162x
Enterprise Value 4.24B 3.8B 3.48B 3.17B 5.98B 399B 6.17B 41.91B 16.71B 213B 15.92B 15.58B 672B EV / Sales 2026 *
14.5x
EV / Sales 2027 * 11.7x
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -
1 day+4.29%
1 week+5.03%
Current month+5.03%
1 month+4.01%
3 months+18.56%
6 months+93.90%
Current year+72.29%
1 week 24.8
Extreme 24.8
28.27
1 month 23.82
Extreme 23.82
29.05
Current year 12
Extreme 12
30.74
1 year 12
Extreme 12
30.74
3 years 2.28
Extreme 2.28
30.74
5 years 2.28
Extreme 2.28
37.55
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap. Importance
10/16/26 A Exercice

Chairperson

35,643 0.0223%
10/13/26 A Exercice

Chairperson

35,643 0.0223%
10/8/26 A Exercice

Chairperson

35,643 0.0223%
Change 5-day change 1-year change 3-year change Capi.($)
+4.29%+5.03%+79.82%+482.92% 4.34B
-4.83%+3.51%+53.62%+61.75% 69.4B
-1.34%+2.98%+24.79%+100.18% 57.62B
+0.02%+1.07%+10.63%+76.66% 57.24B
+5.09%+9.89%+22.45%+107.48% 44.03B
+2.62%+1.68%+28.91%+37.01% 43.65B
+8.24%+0.51%+213.26%+792.66% 38.08B
-1.86%+10.13%+26.82%+53.22% 36.31B
-2.97%-9.84%+88.86%+76.17% 32.61B
-2.18%+7.06%+36.06%-4.95% 25.47B
Average +0.71%+4.30%+58.52%+178.31% 40.88B
Weighted average by Cap. +0.10%+4.27%+52.03%+140.34%

Financials

2026 *2027 *
Net sales 293M 263M 240M 219M 413M 27.57B 426M 2.9B 1.16B 14.71B 1.1B 1.08B 46.43B 360M 323M 295M 269M 508M 33.85B 524M 3.56B 1.42B 18.06B 1.35B 1.32B 57.03B
Net income -85.62M -76.79M -70.18M -64.06M -121M -8.05B -125M -846M -337M -4.29B -321M -314M -13.56B -27.23M -24.42M -22.32M -20.38M -38.39M -2.56B -39.6M -269M -107M -1.37B -102M -100M -4.31B
Net Debt -287M -258M -235M -215M -405M -27B -418M -2.84B -1.13B -14.41B -1.08B -1.05B -45.48B -331M -297M -271M -248M -466M -31.1B -481M -3.27B -1.3B -16.59B -1.24B -1.22B -52.38B
Projected Income Statement - Annual - Adaptive Biotechnologies Corporation
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
06/11/26 $27.98 +4.29% 3,333,525
05/11/26 $26.83 +0.45% 4,045,321
04/11/26 $26.71 +3.53% 2,328,997
03/11/26 $25.80 +2.95% 1,512,841
02/11/26 $25.06 -5.93% 2,337,378
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Adaptive Biotechnologies Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
27.98USD
Average target price
30.21USD
Spread / Average Target
+7.99%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Adaptive Biotechnologies Corporation
  1. Stock Market
  2. Stocks
  3. ADPT Stock